Y Intercept Hong Kong Ltd trimmed its position in shares of Glaukos Corporation (NYSE:GKOS – Free Report) by 27.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,523 shares of the medical instruments supplier’s stock after selling 5,617 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Glaukos were worth $1,564,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Elevation Point Wealth Partners LLC purchased a new position in shares of Glaukos during the first quarter worth $247,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in shares of Glaukos in the 1st quarter valued at $1,007,000. Keybank National Association OH lifted its stake in Glaukos by 1.9% during the 1st quarter. Keybank National Association OH now owns 145,270 shares of the medical instruments supplier’s stock worth $15,640,000 after acquiring an additional 2,764 shares in the last quarter. Inspire Investing LLC lifted its stake in Glaukos by 5.5% during the 1st quarter. Inspire Investing LLC now owns 5,751 shares of the medical instruments supplier’s stock worth $619,000 after acquiring an additional 301 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in Glaukos by 4.3% during the 1st quarter. Pictet Asset Management Holding SA now owns 8,567 shares of the medical instruments supplier’s stock worth $922,000 after acquiring an additional 356 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.
Glaukos Price Performance
Shares of GKOS opened at $154.91 on Friday. The firm has a market capitalization of $9.10 billion, a price-to-earnings ratio of -47.23 and a beta of 0.75. The firm’s fifty day simple moving average is $131.76 and its 200-day simple moving average is $120.46. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $155.70. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10.
Wall Street Analyst Weigh In
Several research firms have weighed in on GKOS. William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. HC Wainwright assumed coverage on shares of Glaukos in a research report on Monday. They set a “buy” rating and a $168.00 price target on the stock. Needham & Company LLC increased their price target on shares of Glaukos from $136.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Piper Sandler reissued an “overweight” rating and issued a $165.00 price objective on shares of Glaukos in a research note on Wednesday, July 1st. Finally, BTIG Research reaffirmed a “buy” rating and set a $162.00 target price on shares of Glaukos in a research note on Wednesday, June 10th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $151.62.
View Our Latest Research Report on GKOS
Insiders Place Their Bets
In other news, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $140.76, for a total transaction of $703,800.00. Following the completion of the transaction, the director directly owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This represents a 12.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Leana Wen sold 1,700 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $143.35, for a total value of $243,695.00. Following the transaction, the director directly owned 19,739 shares of the company’s stock, valued at approximately $2,829,585.65. This represents a 7.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 51,273 shares of company stock valued at $7,332,003 over the last quarter. Corporate insiders own 5.90% of the company’s stock.
About Glaukos
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Stories
- Five stocks we like better than Glaukos
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
